About: Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.92 (-0.95%)
GRCE NASDAQ Grace Therapeutics, Inc.
Grace Therapeutics, Inc. share price
GRCE price activity
Last Price
$1.920
Change (24hr)
-0.02 USD (0.95%)
Volume
66.61K
Volume (4w avg)
-
Open
$1.95
Day Range
$1.87 - $1.98
Previous Close
$1.94
Last Trade
30 Oct, 6:34 pm GMT+0
Delayed
30 Oct, 6:34 pm GMT+0
GRCE price performance
Delayed
30 Oct, 6:34 pm GMT+0
GRCE Market Signals